Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus

Postgraduate Medicine

Volumn 123, Issue 4, 2011, Pages 54-62

  Kruger, Davida F ^a   Boucher, Jackie L ^b   Banerji, Mary Ann ^c  

^a Division of Endocrinology Diabetes Bone and Mineral Disorders   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Guidelines; Incretin; Treatment; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ALGORITHM; BLOOD PRESSURE; BODY MASS; CALORIC INTAKE; CASE REPORT; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET THERAPY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; ESTIMATED AVERAGE GLUCOSE; EXERCISE; FAMILY HISTORY; FIBROMA; GASTROINTESTINAL TOXICITY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INSULIN RELEASE; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; MALE; MEDICAL HISTORY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT COUNSELING; PATIENT MONITORING; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SEDENTARY LIFESTYLE; SELF MONITORING; TREATMENT INDICATION; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 79960292794     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.07.2304     Document Type: Review

References (38)

1. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. Atlanta, GA: CDC; 2011.
2. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
3. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32(12):2225-2229.
4. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006;29(9):2114-2116.
5. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States-no statistically significant change since 2003-2004. NCHS Data Brief. 2007(1):1-8.
6. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282(16):1519-1522.
7. Lindgren CM, McCarthy MI. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab. 2008;4(3):156-163.
8. Edelman S, Henry RR. Diagnosis and Management of Type 2 Diabetes. 8th ed. West Islip, NY: Professional Communications, Inc.; 2007.
9. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
10. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
11. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249-1258.
12. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379-1385.
13. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81-86.
14. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1):S11-S61.
15. National Committee for Quality Assurance. The state of health care quality 2007. http://www.ncqa.org/Portals/0/Publications/Resource%20Library/SOHC/SOHC_07.pdf. Accessed April 16, 2010.
16. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
17. AACE/ACE diabetes algorithm for glycemic control. http://www.aace.com/pub/pdf/GlycemicControlAlgorithmPPT.pdf. Accessed February 3, 2011.
18. Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
19. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16(2):155-156.
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(suppl 1):S62-S69.
21. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478.
22. Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006;22(4):671-681.
23. Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin. 2005;21(2):173-184.
24. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885.
25. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280-285.
26. Schernthaner G, Guerci B, Gallwitz B, et al. Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes. Diabetes Metab. 2010;36(5):389-394.
27. DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649-1655.
28. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643.
29. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65-74.
30. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
31. Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
32. Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med. 2008;10(7):171.
33. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
34. Onglyza (saxagliptin) [package insert]. Princeton, NJ/Wilmington, DE: Bristol-Myers Squibb/AstraZeneca Pharmaceuticals; 2011.
35. Victoza (liraglutide [rDNA origin]) [package insert]. Princeton, NJ: Novo Nordisk, Inc; 2010.
36. Januvia (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2011.
37. Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2011.
38. Byetta (exenatide) [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2010.